ImmunityBio (IBRX) Stock Forecast & Price Target

ImmunityBio is demonstrating promising progress with its targeted and personalized cancer therapies, leveraging a robust technology platform and a lead program with approved status for BCG-unresponsive non-muscle invasive bladder cancer. With a focus on durable bladder preservation and addressing BCG supply limitations, the FDA's acceptance of the company's supplemental Biologics License Application for their papillary bladder cancer treatment supports expansion of their bladder cancer franchise and positions them for potential expansion into papillary-only disease and the larger addressable patient population. Additionally, key leadership on the FDA review team for ImmunityBio's ANKTIVA remains in place and the company does not anticipate an advisory committee meeting ahead of their PDUFA date.

ImmunityBio is likely facing challenges with the FDA's preference for randomized studies, as evidenced by JNJ's difficulties in getting approval for TAR-200 in the papillary population. Meanwhile, the modeling suggests that the company may need to wait until 2028 for approval in the US, with peak sales projections in both the US and EU not reaching significant levels until 2036. The company may also face challenges in demonstrating the efficacy of ANKTIVA + BCG in papillary-only disease, adding further uncertainty to its outlook.